Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands

Karin Worm, Q. Jean Zhou, Christopher T. Saeui, Rosalyn C. Green, Joel A. Cassel, Gabriel J. Stabley, Robert N. DeHaven, Nathalie Conway-James, Christopher J. LaBuda, Michael Koblish, Patrick J. Little, Roland E. Dolle

Research output: Contribution to journalArticlepeer-review

19 Scopus citations


Sulfamoyl benzamides were identified as a novel series of cannabinoid receptor ligands. Starting from a screening hit 8 that had modest affinity for the cannabinoid CB2 receptor, a parallel synthesis approach and initial SAR are described, leading to compound 27 with 120-fold functional selectivity for the CB2 receptor. This compound produced robust antiallodynic activity in rodent models of postoperative pain and neuropathic pain without traditional cannabinergic side effects.

Original languageEnglish
Pages (from-to)2830-2835
Number of pages6
JournalBioorganic and Medicinal Chemistry Letters
Issue number9
StatePublished - May 1 2008


  • Antiallodynic activity
  • Cannabinoid CB receptor
  • Parallel synthesis
  • Structure-activity relationship
  • Sulfamoyl benzamides


Dive into the research topics of 'Sulfamoyl benzamides as novel CB2 cannabinoid receptor ligands'. Together they form a unique fingerprint.

Cite this